Document is current
Any future updates will be listed below
-
Authors
Eilard, Malin Sternby https://orcid.org/0000-0002-5274-7726
Andersson, Mats https://orcid.org/0000-0001-6008-219X
Naredi, Peter https://orcid.org/0000-0002-5652-0422
Geronymakis, Charalampos https://orcid.org/0000-0002-1899-1768
Lindnér, Per
Cahlin, Christian
Bennet, William
Rizell, Magnus https://orcid.org/0000-0001-9791-5247
-
Funding
Funding for this research was provided by:
Bayer HealthCare (15559/2010)
- License Information
-
More Information
Article History
Received: 5 November 2018
Accepted: 27 May 2019
First Online: 11 June 2019
Ethics approval and consent to participate
: The study protocol was approved by the Ethical Review Board in Gothenburg, ref. 053–11, and complementary ethical approval regarding survival was approved in 2017 (Dnr T742–17/053–11). All patients gave oral and written informed consent before study participation. The trial was prospectively registered in the Eudra database with start date 2011-04-07. EudraCT number: 2010–024306-36.
: Not applicable
: The authors declare that they have no competing interest.
